SCHEMBL99435

SCHEMBL99435

COC(=O)CC(OC)OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.48
GAA P10253 4/20 0.43
HSD17B10 Q99714 3/20 0.43
MGAM O43451 2/20 0.43
SI P14410 2/20 0.43
MGAM2 Q2M2H8 2/20 0.43
HTT P42858 3/20 0.36
RECQL P46063 2/20 0.36
KMT2A Q03164 2/20 0.36
TET2 Q6N021 1/20 0.36
MEN1 O00255 1/20 0.36
LMNA P02545 2/20 0.34
CA12 O43570 1/20 0.34
CA14 Q9ULX7 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 4/20 0.34
RAB9A P51151 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ALDH1A1 P00352 3/20 0.33
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27984925 0.97 TSHR (0.46) TSHRGAAHSD17B10MGAMSI
SCHEMBL13211935 0.84 TSHR (0.39) TSHRGAAHSD17B10MGAMSI
SCHEMBL28378728 0.83 ALDH1A1 (0.38) TSHRGAAHSD17B10MGAMSI
SCHEMBL10211016 0.82 GAA (0.44) TSHRGAAHSD17B10MGAMSI
SCHEMBL13644543 0.82 TSHR (0.37) TSHRGAAHSD17B10MGAMSI
SCHEMBL8488294 0.81 TSHR (0.33) TSHRGAAHSD17B10MGAMSI
SCHEMBL13502967 0.81 TSHR (0.33) TSHRGAAHSD17B10MGAMSI
SCHEMBL10211471 0.79 NPC1 (0.44) TSHRGAAHSD17B10MGAMSI
SCHEMBL27230 0.78 TSHR (0.48) TSHRGAAHSD17B10MGAMSI
SCHEMBL1881180 0.77 LMNA (0.42) TSHRGAAHTTRECQLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 982 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3897833-B1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMA (US) 2026-02-04 EP claimed
WO-2025111296-A1 ELECTROLYTE COMPOSITIONS AND ELECTROCHEMICAL DEVICES USING THE SAME II-VI DELAWARE, INC. (US) 2025-05-30 WO claimed
CN-118978438-A Method for co-producing 3, 3-dimethoxy methyl propionate and 3-methoxy methyl acrylate 上海燮宸新材料科技有限公司 2024-11-19 CN claimed
CN-113896637-B Preparation method of 3, 3-dimethoxy methyl propionate 昂吉(上海)环保新材料科技有限公司 2024-06-07 CN claimed
CN-113896634-B Preparation method of 3-methoxy methyl acrylate 昂吉(上海)环保新材料科技有限公司 2024-05-31 CN claimed
CN-113453760-B APOL1 inhibitors and methods of use thereof 弗特克斯药品有限公司 2024-05-24 CN claimed
WO-2023195412-A1 LIGHT EMITTING ELEMENT, DISPLAY DEVICE, METHOD FOR PRODUCING NANOPARTICLE DISPERSION LIQUID, AND NANOPARTICLE DISPERSION LIQUID シャープディスプレイテクノロジー株式会社 2023-10-12 WO claimed
US-20230279010-A1 PROCESSES FOR PREPARING MODULATORS OF ALPHA-1 ANTITRYPSIN VERTEX PHARMACEUTICALS INCORPORATED 2023-09-07 US claimed
EP-4188931-A2 PROCESSES FOR PREPARING MODULATORS OF ALPHA-1 ANTITRYPSIN Vertex Pharmaceuticals Incorporated (US) 2023-06-07 EP claimed
CN-116234809-A Methods of preparing alpha-1 antitrypsin modulators 弗特克斯药品有限公司 2023-06-06 CN claimed
CN-104230990-B 2-((4R, 6S)-6-triphenylphosphine alkene methene base-2,2-is disubstituted-1,3-dioxane-4-yl) acetic acid esters and preparation method thereof and application XINFA PHARMACEUTICAL CO., LTD. (CN) 2016-05-11 CN claimed
CN-104230880-B The simple and convenient process for preparing of 2-((4R, 6R)-6-aminoethyl-2,2-dimethyl-1,3-dioxane-4-yl) acetic acid esters XINFA PHARMACEUTICAL CO., LTD. (CN) 2016-05-04 CN claimed
CN-104230990-A 2-((4R,6S)-6-triphenylphosphoalkenylmethylene-2,2-disubstituted-1,3-dioxyhexacyclo-4-yl)acetate, and preparation method and application thereof XINFA PHARMACEUTICAL CO LTD 2014-12-24 CN claimed
CN-104230880-A Simple preparation method of 2-((4R,6R)-6-aminoethyl-2,2-dimethyl-1,3-dioxyhexacyclo-4-yl)acetate XINFA PHARMACEUTICAL CO LTD 2014-12-24 CN claimed
CN-102924391-A 3,3-dimethoxy-2[2-(2-substituted-4-chlorotriazine oxygen) phenyl] methyl propionate bactericide and synthesis method for same UNIV SICHUAN 2013-02-13 CN claimed
EP-1907503-A1 CORROSION INHIBITOR OR INTENSIFIER FOR USE IN ACIDIZING TREATMENT FLUIDS Halliburton Energy Services, Inc. (US) 2008-04-09 EP claimed
WO-2007007025-A1 CORROSION INHIBITOR OR INTENSIFIER FOR USE IN ACIDIZING TREATMENT FLUIDS HALLIBURTON ENERGY SERVICES, INC. (US) 2007-01-18 WO claimed
US-20070010404-A1 Corrosion inhibitor or intensifier for use in acidizing treatment fluids HALLIBURTON ENERGY SERVICES, INC. 2007-01-11 US claimed
EP-0257557-B1 PROCESS FOR THE PREPARATION OF BIFUNCTIONAL COMPOUNDS BASF Aktiengesellschaft (DE) 1991-12-04 EP claimed
US-4812593-A ZEOLITE CONVERSION OF A TETRALKOXYALKANE OR A DIALKOXYALKANOATE BASF AKTIENGESELLSCHAFT (DE) 1989-03-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279010-A1 PROCESSES FOR PREPARING MODULATORS OF ALPHA-1 ANTITRYPSIN SERPINA2, SERPINC1, SERPINE1 TSHR 588/4885GAA 144/4885HSD17B10 3079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.